Companies in the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval. But with the risk of failure, which could spell disaster for a stock, comes great reward as well. Some companies can see a massive upside just from winning a single midstage trial or even achieving as much as a Fast Track designation from the U.S. Food and Drug Administration (FDA).
Here, 24/7 Wall St. has included a calendar of a few of companies to watch for in the coming week and the rest of June.
Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) is making presentations at the American Diabetes Association on June 22 to 26. Lexicon recently traded at $13.58 a share, with a consensus analyst price target of $23.00 and a 52-week trading range of $7.67 to $18.00.
Endocyte Inc. (NASDAQ: ECYT) will present data in regards to its PSMA-617 at the Society of Nuclear Medicine and Molecular Imaging annual meeting on June 23 to 26. PSMA-617 is a radioligand therapy for the targeted treatment of prostate cancer. Shares of Endocyte were last seen at $13.79 on Friday, with a consensus price target of $17.67 and a 52-week range of $1.17 to $15.45.
Achaogen Inc. (NASDAQ: AKAO) has a Prescription Drug User Fee Act (PDUFA) date scheduled for June 25 for its lead product, plazomicin, which is being developed to treat serious bacterial infections. Achaogen shares traded at $12.42, with a consensus price target of $18.20 and a 52-week range of $9.83 to $25.22.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is readying for its commercial launch of Palynziq (pegvaliase) in the United States, for the treatment of phenylketonuria. Shares of BioMarin were trading at $99.03, with a consensus analyst target of $114.14 and a 52-week range of $75.81 to $99.76.
24/7 Wall St.Global Blood Therapeutics Inc. (NASDAQ: GBT) is expected to announce Part A (dose finding for Part B) of its Phase 3 HOPE trial for people with sickle cell disease later this month. Shares of GBT were last seen at $42.05 on Friday, with a consensus price target of $72.46 and a 52-week range of $24.02 to $68.05.
Ascendis Pharma A/S (NASDAQ: ASND) is expected to present full Phase 1 data from its TransCon-PTH hypoparathyroidism treatment later this month. Shares of Ascendis closed Friday at $66.78, with a consensus analyst target of $80.17 and a 52-week range of $22.25 to $76.29.
Take Charge of Your Retirement In Just A Few Minutes (Sponsor)
Retirement planning doesn’t have to feel overwhelming. The key is finding expert guidance—and SmartAsset’s simple quiz makes it easier than ever for you to connect with a vetted financial advisor.
Here’s how it works:
- Answer a Few Simple Questions. Tell us a bit about your goals and preferences—it only takes a few minutes!
- Get Matched with Vetted Advisors Our smart tool matches you with up to three pre-screened, vetted advisors who serve your area and are held to a fiduciary standard to act in your best interests. Click here to begin
- Choose Your Fit Review their profiles, schedule an introductory call (or meet in person), and select the advisor who feel is right for you.
Why wait? Start building the retirement you’ve always dreamed of. Click here to get started today!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.